Alert: New Earnings Report (3/12/25)-OptimizeRX Corp (NASDAQ: OPRX).

out_logo_500#72150.jpg

OptimizeRX Corp (NASDAQ: OPRX) has reported E.P.S. of $0.00 for its fourth fiscal quarter (ending December 31) versus $-0.23 for the same period a year ago. This performance was $-0.27 short of the consensus estimate of $0.27. For the latest four quarters through December 31, E.P.S. were $-1.10 versus $-1.03 for the same period a year ago.

Recent Price Action

out_mm#72150.jpg
OptimizeRX Corp (NASDAQ: OPRX) stock enjoyed a major increase of 51.7% on 3/12/25. The shares closed at $6.28. Moreover, trading volume in this advance was exceptionally high at 3370% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 18.9% during the last week.

Current PriceTarget Research Rating

OptimizeRX has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. OptimizeRX has a neutral Appreciation Score of 56 but a poor Power Rating of 24, triggering the Negative Value Trend Rating.

Rating Review

In light of this new information and very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.

Be the first to comment

Leave a Reply

Your email address will not be published.


*